Description
ESOSAFE-DSR
is a combination capsule by Arrowin Pharmaceuticals containing Esomeprazole 40mg and Domperidone 30mg in a sustained release formulation, prescribed for the management of gastro-oesophageal reflux disease, peptic ulcers and associated symptoms including heartburn, acid regurgitation and nausea. Gastroenterologists and general physicians across India rely on this combination for its dual-action approach that addresses both excess acid production and impaired gastric motility simultaneously.
GERD is not just an acidity problem. Many patients presenting with heartburn and reflux symptoms also have delayed gastric emptying, where food and acid sit in the stomach longer than normal, increasing the frequency and severity of reflux episodes. Treating acid alone without addressing motility often leads to incomplete symptom resolution, which is why the Esomeprazole and Domperidone combination has become a standard prescription in gastroenterology practice.
Esomeprazole is a proton pump inhibitor and one of the most potent acid suppressants in its class. It works by irreversibly inhibiting the hydrogen-potassium ATPase enzyme system in the gastric parietal cells, the final step in acid secretion. This significantly reduces gastric acid output and maintains an elevated gastric pH for an extended period, creating an environment in which ulcer healing can occur and reflux symptoms are substantially reduced.
Domperidone works through a completely different and complementary pathway. It is a dopamine receptor antagonist that acts on the upper gastrointestinal tract to accelerate gastric emptying and strengthen the lower oesophageal sphincter tone. By moving food out of the stomach faster and reducing the window during which acid can reflux into the oesophagus, Domperidone addresses the root motility cause that Esomeprazole alone cannot resolve. The sustained release formulation ensures that Domperidone is released gradually over the dosing period, maintaining consistent prokinetic activity throughout the day rather than a single peak-and-trough effect.
Composition
Each capsule contains Esomeprazole IP 40mg and Domperidone IP 30mg Sustained Release.
Therapeutic Class
Proton Pump Inhibitor and Prokinetic Agent.
Indications
Esosafe-DSR is indicated for gastro-oesophageal reflux disease, peptic ulcer disease, non-ulcer dyspepsia, symptomatic relief of heartburn and acid regurgitation, nausea associated with gastroparesis, and conditions requiring concurrent acid suppression and improved gastric motility.
Dosage and Administration
One capsule taken orally once daily, preferably 30 to 60 minutes before the first meal of the day. Duration of therapy is determined by the treating physician based on the diagnosis and clinical response. Do not crush or chew the capsule as this disrupts the sustained release mechanism of the Domperidone component.
Packaging
Available in 10×10 and 15×10 ALU-ALU blister packs.
Are There Any Side Effects of Esosafe-DSR?
Esosafe-DSR is generally well tolerated at recommended doses. Commonly reported side effects include headache, diarrhoea, nausea and dry mouth, which are typically mild and transient. Long-term use of proton pump inhibitors such as Esomeprazole has been associated with reduced absorption of magnesium and Vitamin B12 and, in rare cases, with an increased risk of Clostridium difficile-associated diarrhoea. Physicians prescribing long-term PPI therapy should periodically reassess the ongoing clinical need.
Domperidone should be used with caution in patients with cardiac conditions, particularly those with prolonged QT intervals or electrolyte imbalances, as it carries a small risk of cardiac arrhythmia at higher doses. It is contraindicated in patients with prolactinoma or known hypersensitivity to Domperidone. Always use under physician supervision and at the lowest effective dose for the shortest necessary duration.
FAQ Section
What is Esosafe-DSR used for?
Esosafe-DSR is a combination capsule prescribed for GERD, peptic ulcers, heartburn, acid reflux and nausea. It combines a proton pump inhibitor that reduces gastric acid with a prokinetic agent that improves gastric emptying, making it effective for patients with coexisting acidity and motility issues.
Why is Domperidone combined with Esomeprazole in Esosafe-DSR?
Esomeprazole reduces acid production but does not address delayed gastric emptying, which is a key driver of reflux symptoms in many patients. Domperidone accelerates gastric emptying and strengthens the lower oesophageal sphincter, reducing the opportunity for acid to reflux. Together, they provide more complete symptom relief than either drug used alone.
Why does Esosafe-DSR need to be taken before meals?
Proton pump inhibitors like Esomeprazole work best when taken before eating because they must be absorbed and reach parietal cells before food activates them. Taking it 30 to 60 minutes before the first meal ensures maximum acid suppression during the stomach’s most active period.
Can the Esosafe-DSR capsule be opened or chewed?
No. The capsule should be swallowed whole. The Domperidone component is formulated as sustained-release pellets inside the capsule. Crushing or chewing disrupts this mechanism, releasing the full dose at once, eliminating the sustained-release benefit, and potentially increasing the risk of side effects.
Is Esosafe-DSR available for PCD Pharma Franchise?
Yes. Esosafe-DSR is available for PCD distribution with district-wise monopoly rights across pan-India territories. Promotional materials, including visual aids, glossaries and LBLs, are provided. Contact Arrowin Pharmaceuticals to check availability for your district and discuss franchise terms.
If you are looking for a combination with Levosulpiride instead of Domperidone, explore Esosafe-LS : Esomeprazole and Levosulpiride Capsules by Arrowin Pharmaceuticals.
